Good news for Teva: FDA wants more Tysabri testsGlobes - Rishon Le-Zion,Israel... LSE: ELA) announced today that the US Food and Drug Administration (FDA) has notified the companies that it is extending its regulatory review of Tysabri by up ...
Elan, Biogen say FDA to extend review on TysabriABC News - USADUBLIN (Reuters) - Elan and Biogen Idec faced a fresh delay in getting their multiple sclerosis treatment Tysabri back to the market on Wednesday after US ...
Tysabri Approval Still Likely Despite FDA DelayForbes - USABear Stearns maintained an "underperform" rating on Biogen Idec after federal health regulators delayed a decision on whether to allow Tysabri back on the ...See all stories on this topic
Tysabri Likely To Come Back Despite Delaynewratings.com - USA0903 GMT [Dow Jones] Serono +0.2% at CHF928, little moved despite news the FDA extended the regulatory review of Tysabri, a competitor to its leading drug Rebif ...